Human-Derived Antibodies
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
21
NCT05617313
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Phase: Phase 2
Role: Collaborator
Start: Feb 17, 2023
Completion: Jun 26, 2025
Loading map...